Sanofi
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Availability of the Q3 2024 Aide mémoire
Sanofi announced the availability of its Q3 2024 Aide mémoire on the 'Investors' page, aiding in financial modelling with details on non-comparable items, exclusivity losses, foreign currency impact, and share count. Third-quarter results are set for publication on October 25, 2024.
Sanofi sees promise in CD73
Sanofi partners with I-Mab for ulelimumab, a monoclonal antibody targeting CD73, focusing on China for NSCLC treatment alongside Loqtorzi. With 24 CD73 projects in development, ulelimumab aims to prove superior efficacy. Sanofi's recent oncology deals, including this, are modest in scale.
Avantor® Joins Pharmaceutical Industry-Sponsored Energize Virtual Power Purchase Agreement
Avantor enters 10-year virtual power purchase agreement for 25GWh of renewable energy annually from 2026, supporting three new solar projects in Spain. The agreement reflects Avantor's commitment to reducing greenhouse gas emissions and lowering supply chain costs.
Vir Biotechnology stock hits 52-week low at $7.36
Vir Biotechnology's stock hits 52-week low amid market challenges; company appoints new CFO, secures FDA approval, and finalizes licensing deal with Sanofi. Restructuring focuses on viral hepatitis, cutting workforce by 25%. InvestingPro data reveals market cap of $1.01B, negative P/E ratio, and deep negative gross profit margin; analysts advise caution.
Amgen claims success for two immune drugs, but results underwhelm Wall Street
Amgen's Phase 3 results for rocatinlimab in atopic dermatitis and Uplizna in myasthenia gravis were met with skepticism by analysts, who noted rocatinlimab's underwhelming efficacy and safety concerns, while Uplizna's potential as a second-line treatment was seen as sizable but not a threat to market leaders.
Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In ...
Regeneron Pharmaceuticals' P/E, P/B, and P/S ratios are lower than industry averages, suggesting potential undervaluation. High ROE, EBITDA, and gross profit indicate strong profitability, but low revenue growth raises concerns about future performance.
Poland's EU Presidency - Paving the Way for a Competitive Pharmaceutical Industry
Poland's EU Presidency will focus on health, including predictable pharmaceutical legislation, digital healthcare transformation, health prevention initiatives, and vaccination. Sanofi's Michaela Scheiffert highlights the need for balanced legislation to maintain Europe's competitiveness, while Goze Umurhan emphasizes the long-term benefits of vaccination. Sanofi, with significant investments in R&D, aims to lead in AI and immuno-science, contributing to Europe's health security and industrial resilience.
EADV: New data reinforce Sanofi's innovative approach and leadership
Sanofi presents 39 abstracts at EADV 2024, highlighting Dupixent's impact on IL4/IL13 in AD, PN, CSU, and clinical remission in children with AD. Data also showcase pipeline molecules like amlitelimab and rilzabrutinib in AD and CSU.
FDA approves Sarclisa regimen as first-line treatment for myeloma
FDA approves Sanofi's Sarclisa (isatuximab) in combination with VRd for newly diagnosed multiple myeloma patients ineligible for stem cell transplant, based on Phase 3 IMRIOZ trial showing significant reduction in disease progression risk.
UCB, Biogen lupus drug scores in phase 3 trial
UCB and Biogen's phase 3 trial of dapirolizumab pegol for systemic lupus erythematosus (SLE) was successful, with clinical improvement in primary and secondary endpoints. A second trial, PHOENICS FLY, is expected to start before year-end. If approved, dapirolizumab pegol could offer a new treatment for SLE, a chronic autoimmune disease affecting multiple organ systems.
© Copyright 2025. All Rights Reserved by MedPath